-
ESTABLISHING A LEADER IN CELL-BASED IMMUNOTHERAPIES BUILT ON DECADES OF EXPERTISE IN THE FIELD OF ALLOGENEIC DENDRITIC CELL BIOLOGY
Immunicum is listed on NASDAQ Stockholm under the ticker IMMU
Tweets by @Immunicum
Tweets by ImmunicumPress Releases
Immunicum Announces Presentations at Upcoming Scientific Conferences in April and May
19 Apr 2021Immunicum AB (publ) Initiates Research Collaboration with Icahn School of Medicine at Mount Sinai
14 Apr 2021Immunicum AB (publ) Publishes the Annual Report for 2020
12 Apr 2021
Latest Corporate presentation
Immunicum Company PresentationNews
-
Immunicum Investor Event on April 22, 2021 at 1:00 pm CET
19 Apr 2021 -
Corporate Presentation April
7 Apr 2021 -
Corporate Presentation – February 2021
22 Feb 2021 -
Virtual Investor Event Materials
8 Dec 2020 -
Transaction Webcast Presentation
19 Nov 2020
About us
Developing innovative cancer immunotherapies
Immunicum is advancing a novel cell-based approach to treat hematologic and solid tumors.
Learn more
